p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis

Journal of Experimental Medicine

Volumn 210, Issue 3, 2013, Pages 581-603

  Matin, Rubeta N ^a   Chikh, Anissa ^a   Chong, Stephanie Law Pak ^a   Mesher, David ^a   Graf, Manuela ^a   Sanza, Paolo ^a   Senatore, Valentina ^a   Scatolini, Maria ^b   Moretti, Francesca ^c   Leigh, Irene M ^d   Proby, Charlotte M ^d   Costanzo, Antonio ^c   Chiorino, Giovanna ^b   Cerio, Rino ^a   Harwood, Catherine A ^a   Bergamaschi, Daniele ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b Laboratory of Cancer Genomics   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; PROTEIN P63; CKAP4 PROTEIN, HUMAN; MDM2 PROTEIN, HUMAN; MEMBRANE PROTEIN; PROTEIN MDM2; TP53 PROTEIN, HUMAN;

ARTICLE; CANCER RESISTANCE; GENOTOXICITY; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; METASTASIS; MITOCHONDRION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; ADULT; AGED; APOPTOSIS; DNA DAMAGE; DRUG RESISTANCE; FEMALE; FLOW CYTOMETRY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROTEIN TRANSPORT; SKIN TUMOR; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CELL LINE, TUMOR; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; MITOCHONDRIA; PROGNOSIS; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-MDM2; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

MLCS; MLOWN;

EID: 84875740623     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20121439     Document Type: Article

References (128)

1. Akslen, L.A., and O. Mørkve. 1992. Expression of p53 protein in cutaneous melanoma. Int. J. Cancer. 52:13-16. http://dx.doi.org/10.1002/ijc.2910520104
2. Albino, A.P., M.J. Vidal, N.S. McNutt, C.R. Shea, V.G. Prieto, D.M. Nanus, J.M. Palmer, and N.K. Hayward. 1994. Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res. 4:35-45. http://dx.doi.org/10.1097/00008390-199402000-00006
3. Arima, Y., M. Nitta, S. Kuninaka, D. Zhang, T. Fujiwara, Y. Taya, M. Nakao, and H. Saya. 2005. Transcriptional blockade induces p53- dependent apoptosis associated with translocation of p53 to mitochondria. J. Biol. Chem. 280:19166-19176. http://dx.doi.org/10.1074/jbc.M410691200
4. Arnoult, D. 2008. Apoptosis-associated mitochondrial outer membrane permeabilization assays. Methods. 44:229-234. http://dx.doi.org/10.1016/j.ymeth.2007.11.003
5. Avery-Kiejda, K.A., X.D. Zhang, L.J. Adams, R.J. Scott, B. Vojtesek, D.P. Lane, and P. Hersey. 2008. Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNAdamaging agent cisplatin. Clin. Cancer Res. 14:1659-1668. http://dx.doi.org/10.1158/1078-0432.CCR-07-1422
6. Avery-Kiejda, K.A., N.A. Bowden, A.J. Croft, L.L. Scurr, C.F. Kairupan, K.A. Ashton, B.A. Talseth-Palmer, H. Rizos, X.D. Zhang, R.J. Scott, and P. Hersey. 2011. P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. BMC Cancer. 11:203. http://dx.doi.org/10.1186/1471-2407-11-203
7. Azzola, M.F., H.M. Shaw, J.F. Thompson, S.J. Soong, R.A. Scolyer, G.F. Watson, M.H. Colman, and Y. Zhang. 2003. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer. 97:1488-1498. http://dx.doi.org/10.1002/cncr.11196
8. Bae, I., M.L. Smith, M.S. Sheikh, Q. Zhan, D.A. Scudiero, S.H. Friend, P.M. O'Connor, and A.J. Fornace Jr. 1996. An abnormality in the p53 pathway following gamma-irradiation in many wild-type p53 human melanoma lines. Cancer Res. 56:840-847.
9. Baisden, B.L., F.B. Askin, J.R. Lange, and W.H. Westra. 2000. HMB-45 immunohistochemical staining of sentinel lymph nodes: a specific method for enhancing detection of micrometastases in patients with melanoma. Am. J. Surg. Pathol. 24:1140-1146. http://dx.doi.org/10.1097/00000478-200008000-00012
10. Bardeesy, N., K.K. Wong, R.A. DePinho, and L. Chin. 2000. Animal models of melanoma: recent advances and future prospects. Adv. Cancer Res. 79:123-156. http://dx.doi.org/10.1016/S0065-230X(00)79004-X
11. Bártek, J., J. Bártková, B. Vojtešek, Z. Stasková, J. Lukás, A. Rejthar, J. Kovarík, C.A. Midgley, J.V. Gannon, and D.P. Lane. 1991. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene. 6:1699-1703.
12. Belmar-Lopez, C., P. Mancheno-Corvo, M.A. Saornil, P. Baril, G. Vassaux, M. Quintanilla, and P. Martin-Duque. 2008. Uveal vs. cutaneous melanoma. Origins and causes of the differences. Clin. Transl. Oncol. 10:137- 142. http://dx.doi.org/10.1007/s12094-008-0170-4
13. Benchimol, S. 2004. p53-an examination of sibling support in apoptosis control. Cancer Cell. 6:3-4. http://dx.doi.org/10.1016/j.ccr.2004.07.002
14. Bourne, T.D., A.M. Bellizzi, E.B. Stelow, A.H. Loy, P.A. Levine, M.R. Wick, and S.E. Mills. 2008. p63 Expression in olfactory neuroblastoma and other small cell tumors of the sinonasal tract. Am. J. Clin. Pathol. 130:213-218. http://dx.doi.org/10.1309/TEDD2FCWH8W0H4HA
15. Brinck, U., I. Ruschenburg, C.J. Di Como, N. Buschmann, H. Betke, J. Stachura, C. Cordon-Cardo, and M. Korabiowska. 2002. Comparative study of p63 and p53 expression in tissue microarrays of malignant melanomas. Int. J. Mol. Med. 10:707-711.
16. Burford, H.N., A.L. Adams, and O. Hameed. 2009. Effect of storage on p63 immunohistochemistry: a time-course study. Appl. Immunohistochem. Mol. Morphol. 17:68-71. http://dx.doi.org/10.1097/PAI.0b013e31818110de
17. Chan, I., J.I. Harper, J.E. Mellerio, and J.A. McGrath. 2004. ADULT ectodermal dysplasia syndrome resulting from the missense mutation R298Q in the p63 gene. Clin. Exp. Dermatol. 29:669-672. http://dx.doi.org/10.1111/j.1365-2230.2004.01643.x
18. Chehab, N.H., A. Malikzay, M. Appel, and T.D. Halazonetis. 2000. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev. 14:278-288.
19. Chipuk, J.E., U. Maurer, D.R. Green, and M. Schuler. 2003. Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell. 4:371-381. http://dx.doi.org/10.1016/S1535-6108(03)00272-1
20. Chipuk, J.E., L. Bouchier-Hayes, T. Kuwana, D.D. Newmeyer, and D.R. Green. 2005. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science. 309:1732-1735. http://dx.doi.org/10.1126/science.1114297
21. Choi, H.R., J.G. Batsakis, F. Zhan, E. Sturgis, M.A. Luna, and A.K. El-Naggar. 2002. Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis. Hum. Pathol. 33:158-164. http://dx.doi.org/10.1053/hupa.2002.30722
22. Colombari, R., F. Bonetti, G. Zamboni, A. Scarpa, F. Marino, A. Tomezzoli, P. Capelli, F. Menestrina, M. Chilosi, and L. Fiore-Donati. 1988. Distribution of melanoma specific antibody (HMB-45) in benign and malignant melanocytic tumours. An immunohistochemical study on paraffin sections. Virchows Arch. A Pathol. Anat. Histopathol. 413:17-24. http://dx.doi.org/10.1007/BF00844277
23. Dellavalle, R.P., T.B. Egbert, A. Marchbank, L.J. Su, L.A. Lee, and P. Walsh. 2001. CUSP/p63 expression in rat and human tissues. J. Dermatol. Sci. 27:82-87. http://dx.doi.org/10.1016/S0923-1811(01)00105-0
24. Dhillon, P.K., M. Barry, M.J. Stampfer, S. Perner, M. Fiorentino, A. Fornari, J. Ma, J. Fleet, T. Kurth, M.A. Rubin, and L.A. Mucci. 2009. Aberrant cytoplasmic expression of p63 and prostate cancer mortality. Cancer Epidemiol. Biomarkers Prev. 18:595-600. http://dx.doi.org/10.1158/1055-9965.EPI-08-0785
25. Di Como, C.J., M.J. Urist, I. Babayan, M. Drobnjak, C.V. Hedvat, J. Teruya- Feldstein, K. Pohar, A. Hoos, and C. Cordon-Cardo. 2002. p63 expression profiles in human normal and tumor tissues. Clin. Cancer Res. 8:494-501.
26. Dotto, J.E., and E.J. Glusac. 2006. p63 is a useful marker for cutaneous spindle cell squamous cell carcinoma. J. Cutan. Pathol. 33:413-417. http://dx.doi.org/10.1111/j.0303-6987.2006.00477.x
27. el-Deiry, W.S., T. Tokino, T. Waldman, J.D. Oliner, V.E. Velculescu, M. Burrell, D.E. Hill, E. Healy, J.L. Rees, S.R. Hamilton, et al. 1995. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res. 55:2910-2919.
28. Fenouille, N., A. Puissant, M. Tichet, G. Zimniak, P. Abbe, A. Mallavialle, S. Rocchi, J.P. Ortonne, M. Deckert, R. Ballotti, and S. Tartare-Deckert. 2011. SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival. Oncogene. 30:4887-4900. http://dx.doi.org/10.1038/onc.2011.198
29. Flores, E.R., K.Y. Tsai, D. Crowley, S. Sengupta, A. Yang, F. McKeon, and T. Jacks. 2002. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 416:560-564. http://dx.doi.org/10.1038/416560a
30. Flores, E.R., S. Sengupta, J.B. Miller, J.J. Newman, R. Bronson, D. Crowley, A. Yang, F. McKeon, and T. Jacks. 2005. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell. 7:363-373. http://dx.doi.org/10.1016/j.ccr.2005.02.019
31. Fukushima, N., T. Satoh, N. Sueoka, A. Sato, M. Ide, T. Hisatomi, N. Kuwahara, R. Tomimasu, N. Tsuneyoshi, N. Funai, et al. 2006. Clinicopathological characteristics of p63 expression in B-cell lymphoma. Cancer Sci. 97:1050-1055. http://dx.doi.org/10.1111/j.1349-7006.2006.00284.x
32. Gembarska, A., F. Luciani, C. Fedele, E.A. Russell, M. Dewaele, S. Villar, A. Zwolinska, S. Haupt, J. de Lange, D. Yip, et al. 2012. MDM4 is akey therapeutic target in cutaneous melanoma. Nat. Med. 18:1239-1247. http://dx.doi.org/10.1038/nm.2863
33. Glusac, E.J. 2011. The melanoma 'epidemic', a dermatopathologist's perspective. J. Cutan. Pathol. 38:264-267. http://dx.doi.org/10.1111/j.1600-0560.2010.01660.x
34. Gomez-Monterrey, I., A. Bertamino, A. Porta, A. Carotenuto, S. Musella, C. Aquino, I. Granata, M. Sala, D. Brancaccio, D. Picone, et al. 2010. Identification of the Spiro(oxindole-3,3'-thiazolidine)-Based Derivatives as Potential p53 Activity Modulators. J. Med. Chem. 53:8319-8329. http://dx.doi.org/10.1021/jm100838z
35. Gressner, O., T. Schilling, K. Lorenz, E. Schulze Schleithoff, A. Koch, H. Schulze-Bergkamen, A.M. Lena, E. Candi, A. Terrinoni, M.V. Catani, et al. 2005. TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J. 24:2458-2471. http://dx.doi.org/10.1038/sj.emboj.7600708
36. Hameed, O., and P.A. Humphrey. 2005. p63/AMACR antibody cocktail restaining of prostate needle biopsy tissues after transfer to charged slides: a viable approach in the diagnosis of small atypical foci that are lost on block sectioning. Am. J. Clin. Pathol. 124:708-715. http://dx.doi.org/10.1309/JXK1BVATGBVNQ9J9
37. Harmes, D.C., E. Bresnick, E.A. Lubin, J.K. Watson, K.E. Heim, J.C. Curtin, A.M. Suskind, J. Lamb, and J. DiRenzo. 2003. Positive and negative regulation of deltaN-p63 promoter activity by p53 and deltaN-p63-alpha contributes to differential regulation of p53 target genes. Oncogene. 22:7607-7616. http://dx.doi.org/10.1038/sj.onc.1207129
38. Hibi, K., B. Trink, M. Patturajan, W.H. Westra, O.L. Caballero, D.E. Hill, E.A. Ratovitski, J. Jen, and D. Sidransky. 2000. AIS is an oncogene amplified in squamous cell carcinoma. Proc. Natl. Acad. Sci. USA. 97:5462-5467. http://dx.doi.org/10.1073/pnas.97.10.5462
39. Hirao, A., Y.Y. Kong, S. Matsuoka, A. Wakeham, J. Ruland, H. Yoshida, D. Liu, S.J. Elledge, and T.W. Mak. 2000. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science. 287:1824-1827. http://dx.doi.org/10.1126/science.287.5459.1824
40. Hocker, T., and H. Tsao. 2007. Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum. Mutat. 28:578-588. http://dx.doi.org/10.1002/humu.20481
41. Hoek, K., D.L. Rimm, K.R. Williams, H. Zhao, S. Ariyan, A. Lin, H.M. Kluger, A.J. Berger, E. Cheng, E.S. Trombetta, et al. 2004. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res. 64:5270-5282. http://dx.doi.org/10.1158/0008-5472.CAN-04-0731
42. Houben, R., S. Hesbacher, C.P. Schmid, C.S. Kauczok, U. Flohr, S. Haferkamp, C.S. Müller, D. Schrama, J. Wischhusen, and J.C. Becker. 2011. High-level expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 reporter gene assays. PLoS ONE. 6:e22096. http://dx.doi.org/10.1371/journal.pone.0022096
43. Hu, H., S.H. Xia, A.D. Li, X. Xu, Y. Cai, Y.L. Han, F. Wei, B.S. Chen, X.P. Huang, Y.S. Han, et al. 2002. Elevated expression of p63 protein in human esophageal squamous cell carcinomas. Int. J. Cancer. 102: 580-583. http://dx.doi.org/10.1002/ijc.10739
44. Hussein, M.R., A.K. Haemel, and G.S. Wood. 2003. p53-related pathways and the molecular pathogenesis of melanoma. Eur. J. Cancer Prev. 12: 93-100. http://dx.doi.org/10.1097/00008469-200304000-00002
45. Ikawa, S., A. Nakagawara, and Y. Ikawa. 1999. p53 family genes: structural comparison, expression and mutation. Cell Death Differ. 6:1154-1161. http://dx.doi.org/10.1038/sj.cdd.4400631
46. Jacobs, W.B., G. Govoni, D. Ho, J.K. Atwal, F. Barnabe-Heider, W.M. Keyes, A.A. Mills, F.D. Miller, and D.R. Kaplan. 2005. p63 is an essential proapoptotic protein during neural development. Neuron. 48: 743-756. http://dx.doi.org/10.1016/j.neuron.2005.10.027
47. Ji, Z., C.N. Njauw, M. Taylor, V. Neel, K.T. Flaherty, and H. Tsao. 2012. p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition. J. Invest. Dermatol. 132:356-364. http://dx.doi.org/10.1038/jid.2011.313
48. Kakudo, Y., H. Shibata, K. Otsuka, S. Kato, and C. Ishioka. 2005. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s. Cancer Res. 65:2108-2114. http://dx.doi.org/10.1158/0008-5472.CAN-04-2935
49. Kanner, W.A., L.B. Brill II, J.W. Patterson, and M.R. Wick. 2010. CD10, p63 and CD99 expression in the differential diagnosis of atypical fibroxanthoma, spindle cell squamous cell carcinoma and desmoplastic melanoma. J. Cutan. Pathol. 37:744-750. http://dx.doi.org/10.1111/j.1600-0560.2010.01534.x
50. Kanoko, M., M. Ueda, T. Nagano, and M. Ichihashi. 1996. Expression of p53 protein in melanoma progression. J. Dermatol. Sci. 12:97-103. http://dx.doi.org/10.1016/0923-1811(95)00465-3
51. Karst, A.M., D.L. Dai, M. Martinka, and G. Li. 2005. PUMA expression is significantly reduced in human cutaneous melanomas. Oncogene. 24: 1111-1116. http://dx.doi.org/10.1038/sj.onc.1208374
52. Katoh, I., K.I. Aisaki, S.I. Kurata, S. Ikawa, and Y. Ikawa. 2000. p51A (TAp63gamma), a p53 homolog, accumulates in response to DNA damage for cell regulation. Oncogene. 19:3126-3130. http://dx.doi.org/10.1038/sj.onc.1203644
53. Keyes, W.M., Y. Wu, H. Vogel, X. Guo, S.W. Lowe, and A.A. Mills. 2005. p63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes Dev. 19:1986-1999. http://dx.doi.org/10.1101/gad.342305
54. Kilic, E., H.T. Brüggenwirth, M. Meier, N.C. Naus, H.B. Beverloo, J.P. Meijerink, G.P. Luyten, and A. de Klein. 2008. Increased expression of p73Deltaex2 transcript in uveal melanoma with loss of chromosome 1p. Melanoma Res. 18:208-213. http://dx.doi.org/10.1097/CMR.0b013e3283036aa1
55. Knopf, A., C. Plettenberg, A. Pickhard, M. Bas, J. Reifenberger, H. Bier, and V. Balz. 2011. Analysis of the functional integrity of the p53 tumorsuppressor gene in malignant melanoma. Melanoma Res. 21:380-388. http://dx.doi.org/10.1097/CMR.0b013e328347ee04
56. Koga, F., S. Kawakami, Y. Fujii, K. Saito, Y. Ohtsuka, A. Iwai, N. Ando, T. Takizawa, Y. Kageyama, and K. Kihara. 2003. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin. Cancer Res. 9:5501-5507. Koster, M.I., S. Kim, J. Huang, T. Williams, and D.R. Roop. 2006. TAp63alpha induces AP-2gamma as an early event in epidermal morphogenesis. Dev. Biol. 289:253-261. http://dx.doi.org/10.1016/j.ydbio.2005.10.041
57. Koster, M.I., S. Kim, J. Huang, T. Williams, and D.R. Roop. 2006. TAp63alpha induces AP-2gamma as an early event in epidermal morphogenesis. Dev. Biol. 289:253-261. http://dx.doi.org/10.1016/j.ydbio.2005.10.041
58. Kulesz-Martin, M., J. Lagowski, S. Fei, C. Pelz, R. Sears, M.B. Powell, R. Halaban, and J. Johnson. 2005. Melanocyte and keratinocyte carcinogenesis: p53 family protein activities and intersecting mRNA expression profiles. J. Investig. Dermatol. Symp. Proc. 10:142-152. http://dx.doi.org/10.1111/j.1087-0024.2005.200405.x
59. Lassam, N.J., L. From, and H.J. Kahn. 1993. Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res. 53:2235-2238.
60. Leverrier, S., D. Bergamaschi, L. Ghali, A. Ola, G. Warnes, B. Akgül, K. Blight, R. García-Escudero, A. Penna, A. Eddaoudi, and A. Storey. 2007. Role of HPV E6 proteins in preventing UVB-induced release of pro-apoptotic factors from the mitochondria. Apoptosis. 12:549-560. http://dx.doi.org/10.1007/s10495-006-0004-1
61. Li, B., Q. Cheng, Z. Li, and J. Chen. 2010. p53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumors. Cell Cycle. 9:1411-1420.
62. Liefer, K.M., M.I. Koster, X.J. Wang, A. Yang, F. McKeon, and D.R. Roop. 2000. Down-regulation of p63 is required for epidermal UV-B-induced apoptosis. Cancer Res. 60:4016-4020.
63. Little, N.A., and A.G. Jochemsen. 2001. Hdmx and Mdm2 can repress transcription activation by p53 but not by p63. Oncogene. 20:4576-4580. http://dx.doi.org/10.1038/sj.onc.1204615
64. MacPartlin, M., S. Zeng, H. Lee, D. Stauffer, Y. Jin, M. Thayer, and H. Lu. 2005. p300 regulates p63 transcriptional activity. J. Biol. Chem. 280: 30604-30610. http://dx.doi.org/10.1074/jbc.M503352200
65. Mancini, F., G. Di Conza, M. Pellegrino, C. Rinaldo, A. Prodosmo, S. Giglio, I. D'Agnano, F. Florenzano, L. Felicioni, F. Buttitta, et al. 2009. MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. EMBO J. 28:1926-1939. http://dx.doi.org/10.1038/emboj.2009.154
66. Mangiulli, M., A. Valletti, M.F. Caratozzolo, A. Tullo, E. Sbisà, G. Pesole, and A.M. D'Erchia. 2009. Identification and functional characterization of two new transcriptional variants of the human p63 gene. Nucleic Acids Res. 37:6092-6104. http://dx.doi.org/10.1093/nar/gkp674
67. Marchenko, N.D., S. Wolff, S. Erster, K. Becker, and U.M. Moll. 2007. Monoubiquitylation promotes mitochondrial p53 translocation. EMBO J. 26:923-934. http://dx.doi.org/10.1038/sj.emboj.7601560
68. Marchini, S., M. Marabese, E. Marrazzo, P. Mariani, D. Cattaneo, R. Fossati, A. Compagnoni, R. Fruscio, A.A. Lissoni, and M. Broggini. 2008. DeltaNp63 expression is associated with poor survival in ovarian cancer. Ann. Oncol. 19:501-507. http://dx.doi.org/10.1093/annonc/mdm519
69. Massion, P.P., P.M. Taflan, S.M. Jamshedur Rahman, P. Yildiz, Y. Shyr, M.E. Edgerton, M.D. Westfall, J.R. Roberts, J.A. Pietenpol, D.P. Carbone, and A.L. Gonzalez. 2003. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res. 63:7113-7121.
70. Matsuoka, S., M. Huang, and S.J. Elledge. 1998. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science. 282:1893-1897. http://dx.doi.org/10.1126/science.282.5395.1893
71. McGregor, J.M., C.C. Yu, E.A. Dublin, D.M. Barnes, D.A. Levison, and D.M. MacDonald. 1993. p53 immunoreactivity in human malignant melanoma and dysplastic naevi. Br. J. Dermatol. 128:606-611. http://dx.doi.org/10.1111/j.1365-2133.1993.tb00253.x
72. Merlino, G., and F.P. Noonan. 2003. Modeling gene-environment interactions in malignant melanoma. Trends Mol. Med. 9:102-108. http://dx.doi.org/10.1016/S1471-4914(03)00006-6
73. Michaelis, M., F. Rothweiler, S. Barth, J. Cinatl, M. van Rikxoort, N. Löschmann, Y. Voges, R. Breitling, A. von Deimling, F. Rödel, et al. 2011. Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multidrug-resistant cancer cells. Cell Death Dis. 2:e243. http://dx.doi.org/10.1038/cddis.2011.129
74. Mihara, M., and U.M. Moll. 2003. Detection of mitochondrial localization of p53. Methods Mol. Biol. 234:203-209.
75. Mills, A.A. 2006. p63: oncogene or tumor suppressor? Curr. Opin. Genet. Dev. 16:38-44. http://dx.doi.org/10.1016/j.gde.2005.12.001
76. Moll, U.M., N. Marchenko, and X.K. Zhang. 2006. p53 and Nur77/TR3 -transcription factors that directly target mitochondria for cell death induction. Oncogene. 25:4725-4743. http://dx.doi.org/10.1038/sj.onc.1209601
77. Morgan, M.B., C. Purohit, and T.R. Anglin. 2008. Immunohistochemical distinction of cutaneous spindle cell carcinoma. Am. J. Dermatopathol. 30:228-232. http://dx.doi.org/10.1097/DAD.0b013e31816de820
78. Müller, M., E.S. Schleithoff, W. Stremmel, G. Melino, P.H. Krammer, and T. Schilling. 2006. One, two, three-p53, p63, p73 and chemosensitivity. Drug Resist. Updat. 9:288-306. http://dx.doi.org/10.1016/j.drup.2007.01.001
79. Mundt, H.M., W. Stremmel, G. Melino, P.H. Krammer, T. Schilling, and M. Müller. 2010. Dominant negative (DeltaN) p63alpha induces drug resistance in hepatocellular carcinoma by interference with apoptosis signaling pathways. Biochem. Biophys. Res. Commun. 396:335-341. http://dx.doi.org/10.1016/j.bbrc.2010.04.093
80. Muthusamy, V., C. Hobbs, C. Nogueira, C. Cordon-Cardo, P.H. McKee, L. Chin, and M.W. Bosenberg. 2006. Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer. 45:447-454. http://dx.doi.org/10.1002/gcc.20310
81. Narahashi, T., T. Niki, T. Wang, A. Goto, D. Matsubara, N. Funata, and M. Fukayama. 2006. Cytoplasmic localization of p63 is associated with poor patient survival in lung adenocarcinoma. Histopathology. 49:349-357. http://dx.doi.org/10.1111/j.1365-2559.2006.02507.x
82. Nemajerova, A., S. Erster, and U.M. Moll. 2005. The post-translational phosphorylation and acetylation modification profile is not the determining factor in targeting endogenous stress-induced p53 to mitochondria. Cell Death Differ. 12:197-200. http://dx.doi.org/10.1038/sj.cdd.4401526
83. Oda, K., H. Arakawa, T. Tanaka, K. Matsuda, C. Tanikawa, T. Mori, H. Nishimori, K. Tamai, T. Tokino, Y. Nakamura, and Y. Taya. 2000. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell. 102:849-862. http://dx.doi.org/10.1016/S0092-8674(00)00073-8
84. Okada, Y., M. Osada, S. Kurata, S. Sato, K. Aisaki, Y. Kageyama, K. Kihara, Y. Ikawa, and I. Katoh. 2002. p53 gene family p51(p63)-encoded, secondary transactivator p51B(TAp63alpha) occurs without forming an immunoprecipitable complex with MDM2, but responds to genotoxicstress by accumulation. Exp. Cell Res. 276:194-200. http://dx.doi.org/10.1006/excr.2002.5535
85. Osada, M., M. Ohba, C. Kawahara, C. Ishioka, R. Kanamaru, I. Katoh, Y. Ikawa, Y. Nimura, A. Nakagawara, M. Obinata, and S. Ikawa. 1998. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat. Med. 4:839-843. http://dx.doi.org/10.1038/nm0798-839
86. Perez-Losada, J., D. Wu, R. DelRosario, A. Balmain, and J.H. Mao. 2005. p63 and p73 do not contribute to p53-mediated lymphoma suppressor activity in vivo. Oncogene. 24:5521-5524. http://dx.doi.org/10.1038/sj.onc.1208799
87. Petitjean, A., C. Cavard, H. Shi, V. Tribollet, P. Hainaut, and C. Caron de Fromentel. 2005. The expression of TA and DeltaNp63 are regulated by different mechanisms in liver cells. Oncogene. 24:512-519. http://dx.doi.org/10.1038/sj.onc.1208215
88. Polsky, D., K. Melzer, C. Hazan, K.S. Panageas, K. Busam, M. Drobnjak, H. Kamino, J.G. Spira, A.W. Kopf, A. Houghton, et al. 2002. HDM2 protein overexpression and prognosis in primary malignant melanoma. J. Natl. Cancer Inst. 94:1803-1806. http://dx.doi.org/10.1093/jnci/94.23.1803
89. Prince, S., S. Carreira, K.W. Vance, A. Abrahams, and C.R. Goding. 2004. Tbx2 directly represses the expression of the p21(WAF1) cyclindependent kinase inhibitor. Cancer Res. 64:1669-1674. http://dx.doi.org/10.1158/0008-5472.CAN-03-3286
90. Reis-Filho, J.S., P.T. Simpson, L.G. Fulford, A. Martins, and F.C. Schmitt. 2003a. P63-driven nuclear accumulation of beta-catenin is not a frequent event in human neoplasms. Pathol. Res. Pract. 199:785-793. http://dx.doi.org/10.1078/0344-0338-00497
91. Reis-Filho, J.S., P.T. Simpson, A. Martins, A. Preto, F. Gärtner, and F.C. Schmitt. 2003b. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch. 443:122-132. http://dx.doi.org/10.1007/s00428-003-0859-2
92. Ribeiro-Silva, A., L.N. Zambelli Ramalho, S. Britto Garcia, and S. Zucoloto. 2003. The relationship between p63 and p53 expression in normal and neoplastic breast tissue. Arch. Pathol. Lab. Med. 127:336-340.
93. Riley, T., E. Sontag, P. Chen, and A. Levine. 2008. Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 9:402-412. http://dx.doi.org/10.1038/nrm2395
94. Rocca, A., G. Viale, R.D. Gelber, L. Bottiglieri, S. Gelber, G. Pruneri, R. Ghisini, A. Balduzzi, E. Pietri, C. D'Alessandro, et al. 2008. Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression. Cancer Chemother. Pharmacol. 61:965-971. http://dx.doi.org/10.1007/s00280-007-0551-3
95. Rocco, J.W., C.O. Leong, N. Kuperwasser, M.P. DeYoung, and L.W. Ellisen. 2006. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell. 9:45-56. http://dx.doi.org/10.1016/j.ccr.2005.12.013
96. Sakiz, D., T.T. Turkmenoglu, and F. Kabukcuoglu. 2009. The expression of p63 and p53 in keratoacanthoma and intraepidermal and invasive neoplasms of the skin. Pathol. Res. Pract. 205:589-594. http://dx.doi.org/10.1016/j.prp.2009.01.010
97. Sansome, C., A. Zaika, N.D. Marchenko, and U.M. Moll. 2001. Hypoxia death stimulus induces translocation of p53 protein to mitochondria. Detection by immunofluorescence on whole cells. FEBS Lett. 488: 110-115. http://dx.doi.org/10.1016/S0014-5793(00)02368-1
98. Sato, T., F. Han, and A. Yamamoto. 2008. The biology and management of uveal melanoma. Curr. Oncol. Rep. 10:431-438. http://dx.doi.org/10.1007/s11912-008-0066-z
99. Satyamoorthy, K., N.H. Chehab, M.J. Waterman, M.C. Lien, W.S. El-Deiry, M. Herlyn, and T.D. Halazonetis. 2000. Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells. Cell Growth Differ. 11:467-474.
100. Scatolini, M., M.M. Grand, E. Grosso, T. Venesio, A. Pisacane, A. Balsamo, R. Sirovich, M. Risio, and G. Chiorino. 2010. Altered molecular pathways in melanocytic lesions. Int. J. Cancer. 126:1869-1881.
101. Schilling, T., A. Kairat, G. Melino, P.H. Krammer, W. Stremmel, M. Oren, and M. Müller. 2010. Interference with the p53 family network contributes to the gain of oncogenic function of mutant p53 in hepatocellularcarcinoma. Biochem. Biophys. Res. Commun. 394:817-823. http://dx.doi.org/10.1016/j.bbrc.2010.03.082
102. Seitz, S.J., E.S. Schleithoff, A. Koch, A. Schuster, A. Teufel, F. Staib, W. Stremmel, G. Melino, P.H. Krammer, T. Schilling, and M. Müller. 2010. Chemotherapy-induced apoptosis in hepatocellular carcinoma involves the p53 family and is mediated via the extrinsic and the intrinsic pathway. Int. J. Cancer. 126:2049-2066.
103. Senoo, M., J.P. Manis, F.W. Alt, and F. McKeon. 2004. p63 and p73 are not required for the development and p53-dependent apoptosis of T cells. Cancer Cell. 6:85-89. http://dx.doi.org/10.1016/j.ccr.2004.06.005
104. Senoo, M., F. Pinto, C.P. Crum, and F. McKeon. 2007. p63 Is essential for the proliferative potential of stem cells in stratified epithelia. Cell. 129:523-536. http://dx.doi.org/10.1016/j.cell.2007.02.045
105. Serber, Z., H.C. Lai, A. Yang, H.D. Ou, M.S. Sigal, A.E. Kelly, B.D. Darimont, P.H. Duijf, H. Van Bokhoven, F. McKeon, and V. Dötsch. 2002. A C-terminal inhibitory domain controls the activity of p63 by an intramolecular mechanism. Mol. Cell. Biol. 22:8601-8611. http://dx.doi.org/10.1128/MCB.22.24.8601-8611.2002
106. Shieh, S.Y., J. Ahn, K. Tamai, Y. Taya, and C. Prives. 2000. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 14: 289-300.
107. Shields, J.A., C.L. Shields, M. Materin, T. Sato, and A. Ganguly. 2008. Role of cytogenetics in management of uveal melanoma. Arch. Ophthalmol. 126:416-419. http://dx.doi.org/10.1001/archopht.126.3.416
108. Smalley, K.S., R. Contractor, N.K. Haass, A.N. Kulp, G.E. Atilla-Gokcumen, D.S. Williams, H. Bregman, K.T. Flaherty, M.S. Soengas, E. Meggers, and M. Herlyn. 2007. An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res. 67:209-217. http://dx.doi.org/10.1158/0008-5472.CAN-06-1538
109. Sparrow, L.E., R. Soong, H.J. Dawkins, B.J. Iacopetta, and P.J. Heenan. 1995. p53 gene mutation and expression in naevi and melanomas. Melanoma Res. 5:93-100. http://dx.doi.org/10.1097/00008390-199504000-00004
110. Stretch, J.R., K.C. Gatter, E. Ralfkiaer, D.P. Lane, and A.L. Harris. 1991. Expression of mutant p53 in melanoma. Cancer Res. 51:5976-5979.
111. Suh, E.K., A. Yang, A. Kettenbach, C. Bamberger, A.H. Michaelis, Z. Zhu, J.A. Elvin, R.T. Bronson, C.P. Crum, and F. McKeon. 2006. p63 protects the female germ line during meiotic arrest. Nature. 444:624-628. http://dx.doi.org/10.1038/nature05337
112. Tokuyasu, K.T. 1980. Immunochemistry on ultrathin frozen sections. Histochem. J. 12:381-403. http://dx.doi.org/10.1007/BF01011956
113. Tuve, S., T. Racek, A. Niemetz, J. Schultz, M.S. Soengas, and B.M. Pützer. 2006. Adenovirus-mediated TA-p73beta gene transfer increases chemosensitivity of human malignant melanomas. Apoptosis. 11:235-243. http://dx.doi.org/10.1007/s10495-006-3407-0
114. Vance, K.W., S. Carreira, G. Brosch, and C.R. Goding. 2005. Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas. Cancer Res. 65:2260-2268. http://dx.doi.org/10.1158/0008-5472.CAN-04-3045
115. Verhaegen, M., A. Checinska, M.B. Riblett, S. Wang, and M.S. Soengas. 2012. E2F1-dependent oncogenic addiction of melanoma cells to MDM2. Oncogene. 31:828-841. http://dx.doi.org/10.1038/onc.2011.277
116. Walerych, D., G. Kudla, M. Gutkowska, B. Wawrzynow, L. Muller, F.W. King, A. Helwak, J. Boros, A. Zylicz, and M. Zylicz. 2004. Hsp90 chaperones wild-type p53 tumor suppressor protein. J. Biol. Chem. 279: 48836-48845. http://dx.doi.org/10.1074/jbc.M407601200
117. Walerych, D., M.B. Olszewski, M. Gutkowska, A. Helwak, M. Zylicz, and A. Zylicz. 2009. Hsp70 molecular chaperones are required to support p53 tumor suppressor activity under stress conditions. Oncogene. 28:4284-4294. http://dx.doi.org/10.1038/onc.2009.281
118. Wäster, P.K., and K.M. Ollinger. 2009. Redox-dependent translocation of p53 to mitochondria or nucleus in human melanocytes after UVA-and UVB-induced apoptosis. J. Invest. Dermatol. 129:1769-1781. http://dx.doi.org/10.1038/jid.2008.421
119. Weiss, J., M. Heine, K.C. Arden, B. Körner, H. Pilch, R.A. Herbst, and E.G. Jung. 1995. Mutation and expression of TP53 in malignant melanomas. Recent Results Cancer Res. 139:137-154. http://dx.doi.org/10.1007/978-3-642-78771-3_10
120. Westfall, M.D., A.S. Joyner, C.E. Barbieri, M. Livingstone, and J.A. Pietenpol. 2005. Ultraviolet radiation induces phosphorylation and ubiquitin-mediated degradation of DeltaNp63alpha. Cell Cycle. 4: 710-716. http://dx.doi.org/10.4161/cc.4.5.1685
121. Whitesell, L., and S.L. Lindquist. 2005. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer. 5:761-772. http://dx.doi.org/10.1038/nrc1716
122. Yamamoto, K., H. Ichijo, and S.J. Korsmeyer. 1999. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol. Cell. Biol. 19:8469-8478.
123. Yamamoto, M., H. Takahashi, K. Saitoh, T. Horikoshi, and M. Takahashi. 1995. Expression of the p53 protein in malignant melanomas as a prognostic indicator. Arch. Dermatol. Res. 287:146-151. http://dx.doi.org/10.1007/BF01262323
124. Yang, A., and F. McKeon. 2000. P63 and P73: P53 mimics, menaces and more. Nat. Rev. Mol. Cell Biol. 1:199-207. http://dx.doi.org/10.1038/35043127
125. Yang, A., M. Kaghad, Y. Wang, E. Gillett, M.D. Fleming, V. Dötsch, N.C. Andrews, D. Caput, and F. McKeon. 1998. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell. 2:305-316. http://dx.doi.org/10.1016/S1097-2765(00)80275-0
126. Yaziji, H., and A.M. Gown. 2003. Immunohistochemical markers of melanocytic tumors. Int. J. Surg. Pathol. 11:11-15. http://dx.doi.org/10.1177/106689690301100103
127. Zangen, R., E. Ratovitski, and D. Sidransky. 2005. DeltaNp63alpha levels correlate with clinical tumor response to cisplatin. Cell Cycle. 4: 1313-1315. http://dx.doi.org/10.4161/cc.4.10.2066
128. Zerp, S.F., A. van Elsas, L.T. Peltenburg, and P.I. Schrier. 1999. p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesis. Br. J. Cancer. 79:921-926. http://dx.doi.org/10.1038/sj.bjc.6690147